Xilio Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Frankenfield Christopher James unloaded Company’s shares for reported $6841.0 on Jan 02 ’25. In the deal valued at $0.98 per share,6,954 shares were sold. As a result of this transaction, Frankenfield Christopher James now holds 12,421 shares worth roughly $11178.9.
Then, Brennan Kevin M. sold 1,803 shares, generating $1,774 in total proceeds. Upon selling the shares at $0.98, the SVP, FINANCE AND ACCOUNTING now owns 3,197 shares.
Before that, GILEAD SCIENCES, INC. bought 1,759,978 shares. Xilio Therapeutics Inc shares valued at $1,830,377 were divested by the 10% Owner at a price of $1.04 per share. As a result of the transaction, GILEAD SCIENCES, INC. now holds 9,105,451 shares, worth roughly $8.19 million.
Chardan Capital Markets initiated its Xilio Therapeutics Inc [XLO] rating to a Buy in a research note published on December 21, 2022; the price target was $7. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Raymond James began covering XLO with “an Outperform” recommendation on November 16, 2021. Morgan Stanley started covering the stock on November 16, 2021. It rated XLO as “an Overweight”.
Price Performance Review of XLO
On Monday, Xilio Therapeutics Inc [NASDAQ:XLO] saw its stock fall -0.11% to $0.90. Over the last five days, the stock has lost -3.64%. Xilio Therapeutics Inc shares have fallen nearly -5.24% since the year began. Nevertheless, the stocks have risen 37.12% over the past one year. While a 52-week high of $1.93 was reached on 02/12/25, a 52-week low of $0.58 was recorded on 02/04/25. SMA at 50 days reached $0.9581, while 200 days put it at $0.9484.
Levels Of Support And Resistance For XLO Stock
The 24-hour chart illustrates a support level at 0.8167, which if violated will result in even more drops to 0.7284. On the upside, there is a resistance level at 0.9866. A further resistance level may holdings at 1.0682. The Relative Strength Index (RSI) on the 14-day chart is 48.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1238, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.40%. Stochastics %K at 25.23% indicates the stock is a holding.
The most recent change occurred on November 16, 2021 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
